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most advanced malaria vaccine candidate, the RTS,S vaccine based on
the P. falciparum circumsporozoite (CS) protein, has gone through exten-
sive testing in Africa where a recent phase 3 trial showed a 27 and 46%
protection against clinical malaria in African infant and children respec-
tively but unfortunately its efﬁcacy wanes down in a relatively short
time (The RTS, S Clinical Trials Partnership, 2014). The goal of the RTS,S
Clinical Trial Partnership is now to seek a license for the ﬁrst-generationMalaria remains the most prevalent parasitic infection in the world.
Up to 40% of the world population is estimated to be at risk of con-
tracting malaria. This ﬁgure may increase in the future with increasing
temperature brought about by global warming. 207 million cases
(uncertainty interval, 135–287 million) and 627,000 malaria deaths
(uncertainty interval, 473,000–789,000) were estimated in 2013
(WHO, 2013). The majority of the deaths that result from Plasmodium
falciparum infection (the most lethal of the Plasmodium species) occur
among infants, children and prima–gravida women living in sub-
Saharan Africa (WHO, 2013).
Plasmodium vivax, the second malaria species in terms of epidemio-
logical importance but less deadly than P. falciparum, causes ~70–
80 million clinical malaria cases annually with 2.85 billion people living
at risk of infection (Guerra et al., 2010) and generates a substantial eco-
nomic burden worldwide. This parasite species is prevalent mainly in
Asia, Oceania, the Americas, and several countries of Africa, and ac-
counts for half of the malaria cases outside Africa.
The current malaria-control tools in malaria-endemic countries rely
on effective mosquito control and artemisinin-based casemanagement.
Challenges to controlling the burden of disease include the develop-
ment of resistance of Anophelesmosquitoes to certain insecticides; the
development of resistance of malaria parasites to chemotherapeutic
agents (Baird, 2010); the absence of a gametocidal drug suitable for
mass administration (White, 2004), and the risk of re-importation of
malaria into geographic regions despite environmental elimination
measures.
The development of amalaria vaccine is considered as one of themost
cost-effective measures to counter the disease. Valuable progress has
been achieved in the last 30 years in the development of P. falciparum
subunit vaccines (Greenwood and Targett, 2011; Schwartz et al., 2012)
that could be included in the Expanded Program of Immunization (EPI),. This is an open access article undermalaria vaccine. Due to the fact that efﬁcacy was different depending on
the location and transmission rate, this intervention may be approved
only for those regions where the efﬁcacy was highest. In situations
where the RTS,S efﬁcacy is low, the limited available resources may be
better used for other efﬁcacious interventions such as artemisinin-based
combination therapies (ACTs), insecticide-treated mosquito net (ITN)
and indoor residual spraying (IRS).
In addition, prevision for a booster immunization may be consid-
ered, and clinical trials to determine its beneﬁt must also be performed.
This would further reduce resources needed for the interventions men-
tioned above. The homologation of the RTS,S vaccine may also pose a
challenge to the development of alternative vaccines to increase the ef-
ﬁcacy of RTS,S either as combination of RTS,S with new antigens or to-
tally new formulations as discussed recently by Fowkes et al. (Fowkes
et al., 2013), since any new formulation would need to be compared
side-by-side with RTS,S vaccine. It is possible that the most effective
combinations might derive from mixing vaccines that are found efﬁca-
cious when tested alone, that target different stages of parasite life
and/or are based on different mechanisms. In particular, one might
speculate adding to RTS,S the RH5 antigen (whose antibodies are active
in the in vitro inhibition of RBC infection by merozoites of heterologous
P. falciparum strains), or antigens acting in theADCI and/or opsonization
as fragments from MSP2, MSP3, GLURP and PFF0165. Even though sin-
gle antigensmight be only weakly effective, their combination together
with RTS,S is expected to be more effective in controlling the disease
and, as a result, reducing transmission by mosquitoes (Carter and
Chen, 1976).
To this end, efforts should also be made to develop a transmission-
blocking vaccine (The MalERA Consultative Group on Vaccines, 2011).
Known as “altruistic vaccination”, vaccinating in low-prevalence areas
would have no direct beneﬁt at the individual level but would protect
their neighbors from becoming infected. This could be a stand-alone
mosquito-stage vaccine or, more likely, a multi-component vaccine
adding a mosquito-stage component to the partial transmission-
blocking activity of a pre-erythrocytic vaccine. In parallel, morethe CC BY license (http://creativecommons.org/licenses/by/3.0/).
7G. Corradin, I. Nebie / EBioMedicine 1 (2014) 6–7resources should be allocated for testing new P. vivax vaccines and to
determine the mechanisms of protection for this species.
In most malaria-endemic countries, despite the large-scale distribu-
tion of ITN and ACTs, malaria still remains a serious public health prob-
lem. It is hoped that optimization of the current malaria interventions
(e.g., ACTs, ITN, IRS) and the development of an effective and affordable
malaria vaccine will bring an unprecedented rate of life saving and
consequent improvement of life quality for the populations living in
malaria-endemic countries.
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